Individualised Treatment of Alcohol Dependent Patients with Baclofen: A Clinical Observation
نویسندگان
چکیده
Objective: The objective of this observational study was to investigate the effectiveness, safety and tolerability of baclofen in individualised doses for the treatment of alcohol dependence in a sample of patients suffering from additional co-occurring mental disorders. Methods: Fifteen subjects requesting baclofen treatment to achieve abstinence from, or reduction of, alcohol consumption, were included in the study. Baclofen was titrated individually responding to the participants’ reports of drug side effects and reductions in drinking and craving. At the start and the end of the observation period (24 weeks) patients self-reported their number of standard drinks per day and rated their alcohol craving by means of the Obsessive Compulsive Drinking Scale (OCD-S). Liver enzymes, Carbohydrate Deficient Transferrin (CDT) and Ethyl Glucuronide in Hair (HEtG) were measured twice. Results: At the end of the observation period eleven patients were abstinent or low-risk drinking. Mean baclofen dose was 116 mg/d (range 30-225 mg/d). Baclofen was well tolerated and did not interfere with pre-existing pharmacotherapy. Three patients did not benefit from the treatment. The clinical presentation of one patient improved although his alcohol consumption remained higher than the NIAAA recommendations. We observed indications of baclofen misuse in one patient. Conclusion: Baclofen treatment with individually titrated doses between 30 mg/d to 200 mg/d was associated with suppression of, or reduction in, alcohol consumption and craving in the majority of patients. In view of the small sample size, high motivation of the participants, and absence of a control group we caution against an overestimation of our findings. DOI: https://doi.org/10.4172/2161-1459.1000163 Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-102514 Published Version Originally published at: Becker, Martin; Boesch, Lukas; Baumgartner, Markus R; Johnson, David; Stohler, Rudolf (2014). Individualised Treatment of Alcohol Dependent Patients with Baclofen: A Clinical Observation. Clinical Experimental Pharmacology, 4(5):1000163. DOI: https://doi.org/10.4172/2161-1459.1000163 Individualised Treatment of Alcohol Dependent Patients with Baclofen: A Clinical Observation Martin Becker1*, Lukas Boesch1, Markus R Baumgartner2, David Johnson3 and Rudolf Stohler1 1Psychiatric University Hospital, Research Group on Substance Use Disorders, Zurich, Switzerland 2Institute of Forensic Medicine, University of Zurich, Switzerland 3NHS Highland, Argyll & Bute Hospital, Lochgilphead, Argyll, Scotland *Corresponding author: Martin Becker, Psychiatric University Hospital, Selnaustr. 9, 8001 Zürich, Switzerland, Tel: +41 44 555 83 10; Fax: +41 44 317 12 57; E-mail: [email protected] Received: August 15, 2014; Accepted: September 25, 2014; Published: September 30, 2014 Copyright: © 2014 Becker M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
منابع مشابه
Baclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety.
AIM To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the treatment of alcohol dependence. METHODS Out of 69 participants consecutively screened, 42 alcohol-dependent patients were randomized to receive placebo, baclofen 30 mg/day or baclofen 60 mg/day for 12 weeks. All subjects were offered BRENDA, a structured psychosocial therapy for alcohol dependence ...
متن کاملHigh-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial.
Previous randomized, placebo-controlled trials (RCTs) assessing the efficacy of the selective γ-aminobutyric acid (GABA)-B receptor agonist baclofen in the treatment of alcohol dependence have reported divergent results, possibly related to the low to medium dosages of baclofen used in these studies (30-80mg/d). Based on preclinical observations of a dose-dependent effect and positive case repo...
متن کاملGABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence
The present paper summarizes the preclinical and clinical studies conducted to define the "anti-alcohol" pharmacological profile of the prototypic GABAB receptor agonist, baclofen, and its therapeutic potential for treatment of alcohol use disorder (AUD). Numerous studies have reported baclofen-induced suppression of alcohol drinking (including relapse- and binge-like drinking) and alcohol rein...
متن کاملBaclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study.
AIMS The gamma-aminobutyric acid (GABA(B)) receptor agonist, baclofen, has recently been shown to reduce alcohol intake in alcohol-preferring rats and alcohol consumption and craving for alcohol in an open study in humans. The present study was aimed at providing a first evaluation of the efficacy of baclofen in inducing and maintaining abstinence and reducing craving for alcohol in alcohol-dep...
متن کامل[GABAB receptor as therapeutic target for drug addiction: from baclofen to positive allosteric modulators].
The present paper summarizes experimental and clinical data indicating the therapeutic potential of the GABAB receptor agonist, baclofen, in the treatment of alcohol use disorder (AUD) and substance use disorder (SUD). Multiple preclinical studies have demonstrated the ability of baclofen to suppress alcohol drinking (including binge- and relapse-like drinking), oral alcohol self-administration...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2015